A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study.
Yung-Jue Bang
Consultant or Advisory Role - GlaxoSmithKline
Honoraria - GlaxoSmithKline